Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2087 of 2,087 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Primary Biliary Cirrhosis
Interventions: ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more

Conditions: Chronic Idiopathic Constipation
Interventions: Plecanatide; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 2,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 211
States / cities: Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 160 more

Conditions: Mild Alzheimer's Disease
Interventions: Non-invasive brainstem stimulation; Device
Lead sponsor: Scion NeuroStim; Industry
Eligibility: 65 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Boca Raton, Florida • Tampa, Florida • Chapel Hill, North Carolina + 2 more

Conditions: Asthma (Diagnosis)
Interventions: KT-621; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Tampa, Florida • Dallas, Texas

Conditions: Atopic Dermatitis Eczema
Interventions: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 76
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 64 more

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Schizophrenia
Interventions: Aripiprazole once-monthly; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Adult Growth Hormone Deficiency
Interventions: ALTU-238; Drug
Lead sponsor: Altus Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Louisville, Kentucky • Galveston, Texas • San Antonio, Texas

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more

Conditions: Cancer
Interventions: E7389 + carboplatin AUC 5, E7389+carboplatin AUC 6; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more

Conditions: Alzheimer's Disease
Interventions: Rosiglitazone XR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 51 Years to 91 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Palo Alto, California • Deerfield Beach, Florida • Hialeah, Florida + 6 more

Conditions: Cancers, Pain, Lower Back Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Tumors
Interventions: S-1, FT; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut

Conditions: Hypereosinophilic Syndrome
Interventions: mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 10
States / cities: San Diego, California • Denver, Colorado • Bethesda, Maryland + 7 more

Conditions: Recurrent Pericarditis
Interventions: KPL-914; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Conditions: Methylmalonic Acidemia, Propionic Acidemia
Interventions: HST5040, Placebo; Drug
Lead sponsor: HemoShear Therapeutics; Industry
Eligibility: 2 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: San Diego, California • New Haven, Connecticut • Washington D.C., District of Columbia + 11 more

Conditions: Mucopolysaccharidosis II
Interventions: tividenofusp alfa; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: Up to 18 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more

Conditions: Crohn's Disease
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions: TGR-1202, TGR-1202 + Ublituximab; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 17
States / cities: Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 14 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 74
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Las Vegas, Nevada

Search by objective public record fields.

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Aripiprazole Once-monthly in Patients With Schizophrenia

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

A Pilot Study of KPL-914 in Recurrent Pericarditis

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

PK/PD Pediatric ADHD Classroom Study